EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

HAEMATOLOGICAL TOXICITIES OF GEMCITABINE PLUS CISPLATIN VERSUS FLUOROURACIL, CISPLATIN, PLUS DOCETAXEL FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA

Abdul Rehman, Ghulam Haider, Aakash Ramchand, Shumaila Nawaz Khan, Sana Sehar, Raheela Mahmood, Yasir Rehman Khattak, Anaum, Aisha Siddiqa, Muhammad Arsalan Aqeel

Journal of Ayub Medical College Abbottabad · 2024

DOI: 10.55519/jamc-01-12489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ayub Medical College Abbottabad, 2024. Verfasst von Abdul Rehman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jinnah Postgraduate Medical Centre (JPMC) Karachi-Pakistan. Hauptthemen laut MEDLINE: Cisplatin, Docetaxel, Nasopharyngeal Neoplasms, Fluorouracil. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nasopharyngeal carcinoma is endowed with unique epidemiological characteristics, treatment modalities, and prognostic considerations. Patients with bulky primary tumours and extensive nodal involvement are categorized as locoregionally advanced NPC. These patients present a high-risk cohort in terms of the unfavourable prognostic features. In this patient cohort, the 5-year local control rates have been observed to fluctuate within the range of 69-79%. The objective was the assessment of the local control and adverse haematological toxicity profiles of neoadjuvant chemotherapy (NACT) (i.e., docetaxel, cisplatin, plus fluorouracil (TCF) and gemcitabine plus cisplatin (GC)) followed by concurrent chemoradiotherapy (CCRT) in patients with locoregionally advanced nasopharyngeal carcinoma (LANPC) was the primary objective of this work.

Methods

Patients aged 16-65 years, confirmed NPC, stage III-IVA disease and ECOG performance score ‰¤2 were enrolled in this prospective study. Besides the common CCRT regimen, the patients received NACT with docetaxel 30 mg/m2, cisplatin 40 mg/m2 plus fluorouracil 750 mg/m2 (Group I) or gemcitabine 1 g/m2 plus cisplatin 80 mg/m2 (Group II). At 6 weeks after completion of CCRT, treatment response was assessed with the RECIST criteria. Adverse haematological events were evaluated with peripheral white blood cells, neutrophils, haemoglobin, and platelets after each cycle of NACT.

Results

Of the total 68 enrolled patients with locoregionally advanced NPC (LANPC), 50 (73.5%) were male patients. Group I consisted of 36, while Group II comprised 32 patients. The mean (interquartile range) age of the patients in Group I was 40.9±11.6 (30.3-51.8) years, while in Group II was 38.6±11.3 (29.5-51.0) years. Complete response (CR) of the treatment was higher and partial response (PR) was lower in Group II compared to Group I (71.9% vs. 44.4% and 18.6% vs. 50%, respectively). Haematological toxicity profiles were consistent in Groups I and II, illustrating mild anaemia and lymphopenia, severe neutropenia and a mixed pattern of thrombocytopenia.

Conclusion

Among patients with LANPC, GC-based NACT showed superior CR compared with TCF-based NACT. However, the haematological toxicity profiles in the two groups were comparable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinDocetaxelNasopharyngeal NeoplasmsFluorouracilNasopharyngeal CarcinomaAntineoplastic Combined Chemotherapy ProtocolsGemcitabineChemoradiotherapyDeoxycytidineHumansMaleMiddle AgedAdultFemaleAdolescentYoung AdultProspective StudiesAgedNeoadjuvant Therapy

Stichwörter der Autor:innen

Imaging; Haematological toxicity; Neoadjuvant chemotherapy; Diagnosis

Substanzen

CisplatinDocetaxelFluorouracilGemcitabineDeoxycytidine

Autor:innen und Institutionen

  • Jinnah Postgraduate Medical Centre (JPMC) Karachi-Pakistan.
  • Atomic Energy Medical Centre, JPMC Karachi Pakistan.
  • Hayatabad Medical Complex, Peshawar-Pakistan.
  • Jinnah Postgraduate Medical Centre (JPMC) Karachi, Pakistan.

Zitieren

APA

Rehman, A., Haider, G., Ramchand, A., Khan, S. N., Sehar, S., Mahmood, R., Khattak, Y. R., Anaum, Siddiqa, A., & Aqeel, M. A. (2024). HAEMATOLOGICAL TOXICITIES OF GEMCITABINE PLUS CISPLATIN VERSUS FLUOROURACIL, CISPLATIN, PLUS DOCETAXEL FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA. Journal of Ayub Medical College Abbottabad. https://doi.org/10.55519/jamc-01-12489

Vancouver

Rehman A, Haider G, Ramchand A, Khan SN, Sehar S, Mahmood R, et al. HAEMATOLOGICAL TOXICITIES OF GEMCITABINE PLUS CISPLATIN VERSUS FLUOROURACIL, CISPLATIN, PLUS DOCETAXEL FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA. Journal of Ayub Medical College Abbottabad. 2024. doi:10.55519/jamc-01-12489

BibTeX
@article{Rehman2024,
  author = {Rehman, Abdul and Haider, Ghulam and Ramchand, Aakash and Khan, Shumaila Nawaz and Sehar, Sana and Mahmood, Raheela and Khattak, Yasir Rehman and Anaum, Anaum and Siddiqa, Aisha and Aqeel, Muhammad Arsalan},
  title = {HAEMATOLOGICAL TOXICITIES OF GEMCITABINE PLUS CISPLATIN VERSUS FLUOROURACIL, CISPLATIN, PLUS DOCETAXEL FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA},
  journal = {Journal of Ayub Medical College Abbottabad},
  year = {2024},
  doi = {10.55519/jamc-01-12489}
}
Kostenlos starten →